Related references
Note: Only part of the references are listed.Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
Martina Benesova et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Quantitative SPECT/CT Imaging of 177Lu with In Vivo Validation in Patients Undergoing Peptide Receptor Radionuclide Therapy
J. C. Sanders et al.
MOLECULAR IMAGING AND BIOLOGY (2015)
Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
Christian M. Zechmann et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer
Gregory R. Pond et al.
EUROPEAN UROLOGY (2014)
Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
Damian Wild et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes
Michael F. Gensheimer et al.
RADIATION ONCOLOGY (2014)
Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
Scott T. Tagawa et al.
CLINICAL CANCER RESEARCH (2013)
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
A. Afshar-Oromieh et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John J. Zaknun et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing Lu-177-DOTA-Octreotate Treatment
Mattias Sandstrom et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Minor changes in effective half-life during fractionated 177Lu-Octreotate therapy
Ulrike Garske et al.
ACTA ONCOLOGICA (2012)
Lutetium-labelled peptides for therapy of neuroendocrine tumours
B. L. R. Kam et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Yttrium-labelled peptides for therapy of NET
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy
Yuni K. Dewaraja et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
Rafael Lozano et al.
LANCET (2012)
Quantitative Bremsstrahlung SPECT/CT image reconstruction with patient specific Monte Carlo scatter compensation for Y-90 microsphere radioembolization (RE)
Yuni Dewaraja et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Parotid gland-recovery after radiotherapy in the head and neck region-36 months follow-up of a prospective clinical study
Jeremias Hey et al.
RADIATION ONCOLOGY (2011)
EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry
Cecilia Hindorf et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
Flavio Forrer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prostate-specific membrane antigen expression in regeneration and repair
Ilyssa O. Gordon et al.
MODERN PATHOLOGY (2008)
Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry
A. C. Traino et al.
PHYSICS IN MEDICINE AND BIOLOGY (2007)
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
NH Bander et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
A Ghosh et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
MI Milowsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A generalized model for the conversion from CT numbers to linear attenuation coefficients
CY Bai et al.
IEEE TRANSACTIONS ON NUCLEAR SCIENCE (2003)
Physical models and dose factors for use in internal dose assessment
MG Stabin et al.
HEALTH PHYSICS (2003)
The two types of correction of absorbed dose estimates for internal emitters
LE Williams et al.
CANCER (2002)
Share Paper
